U.S. markets closed
  • S&P Futures

    4,069.00
    -6.50 (-0.16%)
     
  • Dow Futures

    34,421.00
    -38.00 (-0.11%)
     
  • Nasdaq Futures

    11,987.50
    -22.75 (-0.19%)
     
  • Russell 2000 Futures

    1,892.70
    -1.70 (-0.09%)
     
  • Crude Oil

    80.57
    +0.59 (+0.74%)
     
  • Gold

    1,821.20
    +11.60 (+0.64%)
     
  • Silver

    23.50
    +0.25 (+1.05%)
     
  • EUR/USD

    1.0584
    +0.0054 (+0.51%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • Vix

    19.06
    -0.78 (-3.93%)
     
  • GBP/USD

    1.2342
    +0.0046 (+0.37%)
     
  • USD/JPY

    134.3030
    +0.0320 (+0.02%)
     
  • BTC-USD

    17,261.00
    +269.25 (+1.58%)
     
  • CMC Crypto 200

    409.13
    +7.71 (+1.92%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,772.33
    -5.57 (-0.02%)
     

Palatin to Participate in Ladenburg Thalmann Healthcare Conference

CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022.

Palatin Technologies, Inc.
Palatin Technologies, Inc.

Carl Spana, Ph.D., President and Chief Executive Officer will present an update on the Company's pipeline and participate in an Analyst led Fireside Chat.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with highly potent, targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Vyleesi and other Palatin products in development, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, Palatin's ability to establish and maintain the capability for manufacturing, marketing and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-participate-in-ladenburg-thalmann-healthcare-conference-301637093.html

SOURCE Palatin Technologies, Inc.